Description
“ Janus Kinase ( JAK ) Inhibitors - Competitive Landscape , Technology and Pipeline Analysis , 2016 ”, report provides comprehensive insights about pipeline drugs across this Mechanism of action . Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Janus Kinase ( JAK ) Inhibitors .
Request a sample of this report @ http :// www . orbisresearch . com / contacts / request-sample / 209358 .
Janus Kinases belong to the group of cytoplasmic non -receptor Tyrosine kinases ( NRTKs ). JAKs are associated with cytokine receptors present on the surface of cells . NRTKs are primarily involved in signal transduction originating from extracellular ligands , which often interact with transmembrane receptors . They are key component in mediating signaling process such as expression of genes which are involved in proliferation , apoptosis , migration , differentiation . Janus family of kinases comprised of JAK1 , JAK2 , JAK3 and tyrosine kinase 2 ( TYK2 ). They play a major role in immune defense .
Purchase a copy of this report @ http :// www . orbisresearch . com / contact / purchase / 209358 .
This report provides information on the therapeutic development based on JAK Inhibitors mechanism of action dealing with 2 marketed drugs ( Tofacitinib & Ruxolitinib ) and 36 active pipeline drugs . The report also covers the information for 26 + active companies involved in the therapeutic development of the products . The report also includes the information related to discontinued and dormant drugs . There are 9 discontinued and 16 dormant products .
Report Highlights :
• The report also includes the information regarding the marketed drugs and their current clinical status for various other indications for which they may receive approval in near future .
• This report also has market analysis that covers various deals , agreements , collaborations , acquisitions between various pharma giants and mid-level companies for successful development and future growth of drugs based on this mechanism of acti on .
• This report provides information on the therapeutic development based on the Janus Kinase ( JAK ) Inhibitors dealing with all the marketed and pipeline drugs .
• The report provides drug profile , which includes product description , MOA , licensors & collaborators , development partner and chemical information .
• This report covers the comparative analysis of Janus Kinase ( JAK ) Inhibitors at various stages covering Marketed , Filed , Phase III , Phase II , Phase I , IND filed , Preclinical , Discovery and unknown stages , therapeutics assessment by monotherapy and combination products and molecule type drug
www . orbisresearch . com ; + 1 ( 214 ) 884-6817 ; + 9120-64101019